Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 139

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 4
Chunk 139
---
 our Initial Public Offering, see Part I, Item 2 of this report.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

24

Item 6. Exhibits.

The following exhibits are filed as part of, or incorporated by reference
into, this report:

    No.
     
    Description of Exhibit
  
    31.1
     
    Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
  
    31.2
     
    Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
  
    32.1*
     
    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  
    32.2*
     
    Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  
    101.CAL
     
    XBRL Taxonomy Extension Calculation Linkbase Document
  
    101.SCH
     
    XBRL Taxonomy Extension Schema Document
  
    101.DEF
     
    XBRL Taxonomy Extension Definition Linkbase Document
  
    101.LAB
     
    XBRL Taxonomy Extension Labels Linkbase Document
  
    101.PRE
     
    XBRL Taxonomy Extension Presentation Linkbase Document
  
    104
     
    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Furnished
herewith

25

SIGNATURES

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.

    Date: August 14, 2025
    DRUGS